October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Five candidates are now in phase III trials in the West, as Pfizer approaches its first interim readout.
More details on an adverse event in a trial of Astrazeneca's AZD1222 will be needed to assess the fallout for other vaccine developers.
Moderna gets a boost from data in older subjects and a potential logistical advantage.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
Encouraging immune responses and a competitive safety profile in a small trial seem to make Novavax’s vaccine a contender.